There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on InMode (INMD – Research Report), Ocular Therapeutix (OCUL – Research Report) and Adverum Biotechnologies (ADVM – Research Report) with bullish sentiments.
InMode (INMD)
In a report issued on December 6, Jeff Johnson from Robert W. Baird maintained a Buy rating on InMode, with a price target of $32.00. The company’s shares closed last Friday at $21.74, close to its 52-week low of $18.57.
According to TipRanks.com, Johnson is a 5-star analyst with an average return of
InMode has an analyst consensus of Moderate Buy, with a price target consensus of $31.80, representing a 53.2% upside. In a report issued on November 28, Barclays also maintained a Buy rating on the stock with a $45.00 price target.
See the top stocks recommended by analysts >>
Ocular Therapeutix (OCUL)
Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on Ocular Therapeutix on December 6 and set a price target of $18.00. The company’s shares closed last Friday at $3.62.
According to TipRanks.com, Kusy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Ocular Therapeutix is a Strong Buy with an average price target of $12.50, implying a 235.1% upside from current levels. In a report issued on December 4, JMP Securities also reiterated a Buy rating on the stock with a $12.00 price target.
Adverum Biotechnologies (ADVM)
In a report issued on December 6, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Adverum Biotechnologies, with a price target of $2.00. The company’s shares closed last Friday at $0.90.
According to TipRanks.com, Suvannavejh is ranked 0 out of 5 stars with an average return of
Adverum Biotechnologies has an analyst consensus of Strong Buy, with a price target consensus of $3.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on INMD:
